Q-omics provides the consensus-scored KIF7 profile across patient tissues and cancer cell-line models. KIF7 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, KIF7 is differentially expressed in 11, with the highest sampling consensus in HNSC. Additionally, KIF7 RNA expression shows 19,240 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight UVM, HNSC, and ACC as cancer lineages where KIF7 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for KIF7 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes KIF7 survival associations across molecular data types. KIF7 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (7) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible KIF7 RNA expression–survival associations across cancer types. High KIF7 expression shows unfavorable associations in ACC, MESO, KIRC, COAD and KIRP, but favorable associations in UVM. The UVM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for KIF7 RNA expression.
This table summarizes KIF7 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 3. The strongest signals are observed in HNSC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for KIF7. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. KIF7 shows lower tumor expression in BLCA, BRCA and THCA and higher tumor expression in HNSC, LIHC and KIRC. The HNSC box plot shows higher KIF7 RNA expression in tumor versus normal tissue (log2 FC = +1.128, t-test p < 0.001).
This table shows molecular features associated with KIF7 in patient tissues and cancer cell lines. In patient samples, KIF7 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, KIF7 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in URINARY_TRACT, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and LARGE_INTESTINE.
